In recent years, the pathogenesis of hematological disorders in children has been
clariied, which has led to remarkable progress in the treatment outcome for these
disorders. In particular, molecular targeted therapy has been shown to have an effect
on childhood leukemia refractory to conventional therapy. Further development of these strategies will enable us to use more effective and less toxic therapies for hematological disorders in the future. Here we describe the pathogenesis and treatment
(present and future) of several representative hematological disorders in children,
especially focusing on the genetic and molecular aspects.
Most hematological disorders in children arise from intrauterine endogenous or exogenous exposures, genetic susceptibility, or several factors after birth. A good example is the case of infant leukemia. Greaves et al.
Part I: Hematopoiesis
Part II: White Blood Cell Disorders
Part III: Red Blood Cell Disorders
Part IV: Platelet and Coagulation Disorders
Part V: Histiocytic Disorders
Title: Hematological Disorders in Children
Author: Eiichi Ishii